Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.
Sylvia C. Kurz, MD, PhD
Advertisement
Sylvia C. Kurz, MD, PhD, is the interim section chief for Neuro-oncology and co-director of the Chenevert Brain Tumor Center at Yale Cancer Hospital.
Articles by Sylvia C. Kurz, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5